Koji Fukushima
Overview
Explore the profile of Koji Fukushima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
740
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butic A, Katz Z, Jin G, Fukushima K, Hazama M, Lukacher A, et al.
mBio
. 2024 Jul;
15(8):e0104924.
PMID: 38953354
Importance: Widespread in the human population and able to persist asymptomatically for the life of an individual, polyomavirus infections cause a significant disease burden in the immunocompromised. Individuals undergoing immune...
2.
Fukushima K, Yoshida T, Yamazaki H, Takamatsu N, Nagai T, Osaki Y, et al.
Intern Med
. 2023 Nov;
63(12):1813-1817.
PMID: 37926535
We herein report a 12-year-old boy who presented with a fever, erythematous rash on the cheeks, back pain, and dysphagia. Blood tests revealed increased creatine kinase levels, and muscle ultrasonography...
3.
Hanada K, Osaki Y, Fujita K, Fukumoto T, Fukushima K, Kito H, et al.
Intern Med
. 2023 Sep;
62(18):2743-2746.
PMID: 37722924
We herein report a 90-year-old immunocompromised woman who developed right upper limb weakness and right ptosis with a miotic pupil 1 week after oral therapy for zoster on the right...
4.
Yoshida T, Yamazaki H, Nishimori Y, Takamatsu N, Fukushima K, Osaki Y, et al.
Muscle Nerve
. 2023 Apr;
68(1):39-47.
PMID: 37118940
Introduction/aims: In idiopathic inflammatory myopathies (IIMs), the change in muscle echogenicity and its histopathological basis are not well understood. We quantitatively measured muscle echogenicity in patients with IIMs and evaluated...
5.
Ishizawa K, Yokoyama M, Kato H, Yamamoto K, Makita M, Ando K, et al.
Cancer Chemother Pharmacol
. 2022 Jul;
90(1):83-95.
PMID: 35796785
Purpose: This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma...
6.
Fukushima K, Takamatsu N, Yamamoto Y, Yamazaki H, Yoshida T, Osaki Y, et al.
Clin Neurophysiol
. 2022 Jun;
140:136-144.
PMID: 35772191
Objective: Although fasciculation on muscle ultrasonography (MUS) is useful in diagnosing amyotrophic lateral sclerosis (ALS), its applicability to early diagnosis remains unclear. We aimed to develop and validate diagnostic models...
7.
Yamazaki H, Matsui N, Takamatsu N, Yoshida T, Fukushima K, Takata T, et al.
Neuromuscul Disord
. 2022 Jun;
32(7):590-593.
PMID: 35672204
Eosinophilic fasciitis (EF) is a rare disorder characterized by muscle stiffness mimicking other neuromuscular diseases. The diagnosis of EF is made on the basis of typical skin lesions. We report...
8.
Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, et al.
Ann Hematol
. 2022 Mar;
101(5):979-989.
PMID: 35244756
This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell lymphoma (rrDLBCL)....
9.
Hanaoka N, Hazama M, Fukushima K, Fujimoto T
Microbiol Spectr
. 2022 Feb;
10(1):e0156921.
PMID: 35171015
Human mastadenovirus (HAdV), a linear double-stranded DNA (dsDNA) virus, is the causal agent of several diseases, including pharyngoconjunctival fever, epidemic keratoconjunctivitis, and hemorrhagic cystitis, in immunocompromised individuals. There are more...
10.
Nakayama M, Kobayashi H, Takahara T, Nishimura Y, Fukushima K, Yoshizawa K
Gynecol Oncol
. 2016 Sep;
143(2):246-251.
PMID: 27612976
Background: In clinical practice, 40mg/m of pegylated liposomal doxorubicin (PLD40) has been used as an initial dosage for treating recurrent epithelial ovarian cancer (OC) instead of the recommended dose of...